Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALT-803 for Relapsed Hematologic Malignancy Post-Transplant
NCT01885897Phase 2Completed
- Sponsor
- Masonic Cancer Center
- Start
- Nov 2013
- Primary completion
- Jul 2019
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of nogapendekin alfa inbakicept in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS), lymphoma, multiple myeloma (MM), sponsored by Masonic Cancer Center. Started Nov 2013; status: completed.
02
Drugs
nogapendekin alfa inbakicept
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)lymphomamultiple myeloma (MM)
Beyond the preview
Go deeper on NCT01885897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01885897.